Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05732051 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients

Study acronym: NARNIA
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 17, 2023 (before its estimated August 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Primary endpoint revised · Start date changed from estimate of Mar 1, 2023 to Mar 16, 2023 · Secondary endpoints revised (8) · 3 morev2 Show 6 more changesShow less
    • Primary endpoint revised
    • Start date changed from estimate of Mar 1, 2023 to Mar 16, 2023
    • Secondary endpoints revised (8)
    • Study description expanded, about 134 words
    • Site details revised
    • Eligibility criteria shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. In this study, the investigators want to evaluate whether nicotinamide riboside can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline therapy. Further, the investigators will evaluate change in signs of skeletal muscle injury and functional capacity.
Trial Details
NCT Number NCT05732051
Lead Sponsor University Hospital, Akershus
Collaborators: ChromaDex, Inc., Norwegian Cancer Society, Norwegian Breast Cancer Association, Helse Sor-Ost
Conditions Breast Cancer, Metastatic Breast Cancer, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity, Heart Failure
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov